Anderson Hoagland 13F: Adds $1.1M to Eli Lilly and (LLY) Stake
Key Points
- Anderson Hoagland increased its holdings in Eli Lilly by 860 shares, a 3.75% increase, now totaling 23,796 shares valued at about $31.1 million.
- As of October 27, 2026, Eli Lilly shares traded around $1,279.16, slightly above the October 23 closing price of $1,273.46.
- The company's next earnings report is scheduled for October 29, 2026, and analysts maintain a positive outlook with a consensus target price of $1,331.55.
Since the filing, $LLY is up 0.5% to date (from the $1,273.46 close on Oct 23, 2026).
Get Eli Lilly and Company text alerts
We text you when insiders, Congress, analysts or big funds move on $LLY.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Eli Lilly and Company alert may contain errors. Disclosures
On October 23, 2026, Anderson Hoagland boosted its stake in Eli Lilly and Company (LLY) by 860 shares.
LLY
Eli Lilly and Company
Anderson Hoagland vs. the S&P 500
Hypothetical returns from Anderson Hoagland's disclosed trades, not real profit or advice. How we model this.
What Changed in Anderson Hoagland's Eli Lilly Position
Anderson Hoagland added 860 shares to its Eli Lilly position, which represents a 3.75% increase. The reported value of this change is about $1.1 million, and it reflects the firm’s continued confidence in the healthcare sector.
Where Eli Lilly Fits in Anderson Hoagland's Portfolio
Eli Lilly now makes up 5.41% of Anderson Hoagland's portfolio, ranking 6th among its 134 reported positions.
Other Institutional Activity in Eli Lilly
Other institutional investors have also adjusted their positions in Eli Lilly. Midwest Trust grew its holdings by 5,069 shares, totaling 73,312 shares valued at about $84.8 million. Meanwhile, Perigon Wealth Management reduced its stake by 10,705 shares, bringing its total to 26,608 shares worth around $30.8 million. Signaturefd added 961 shares, increasing its position to 27,035 shares valued at about $31.3 million.
Eli Lilly and Company Stock Up 0.4%
Eli Lilly shares closed at $1,273.46 on October 23, 2026, and have since traded recently around $1,279.16. This recent price is about 0.4% above the closing price on the filing date and shows a strong performance as it trades above both the 50-day and 200-day moving averages by 7.8% and 17.9%, respectively.
Recent Earnings
Eli Lilly reported trailing twelve-month revenue of approximately $79.7 billion and an EPS of $29.79. The company has shown significant growth, with a year-over-year revenue growth of 47.7%. The next earnings report is set for October 29, 2026.
Dividend
Eli Lilly pays an annual dividend of $6.92 per share, which gives it a yield of 0.54%. The dividend payout ratio stands at 21.7%, indicating a healthy balance between returning capital to shareholders and reinvesting in the business.
Insider Buying and Selling at Eli Lilly and Company
Recent insider activity includes several sales. Anat Hakim, the General Counsel, sold 5,000 shares at an average price of $1,190.00 on August 7, 2026, totaling $5.95 million. Officer Donald A. Zakrowski sold 2,000 shares at $1,185.01 on August 10, 2026, worth $2.37 million. Another officer, Patrik Jonsson, sold 6,500 shares at $1,175.10 on August 17, 2026, for about $7.64 million. These transactions occurred before the recent 13F filing and do not imply any negative sentiment towards the company's outlook.
Analysts Set New Price Targets
Analysts remain optimistic about Eli Lilly's prospects. On September 28, 2026, JP Morgan maintained an Overweight rating with a price target of $1,500. Morgan Stanley followed suit on October 7, also maintaining an Overweight rating with a target of $1,430. Cantor Fitzgerald and RBC Capital have similar positive views, projecting targets of $1,440 and $1,500, respectively. The consensus target price is $1,331.55 based on 30 analyst opinions.
About Eli Lilly
Eli Lilly and Company is a major player in the healthcare sector, focusing on discovering, developing, manufacturing, and marketing pharmaceutical products globally. The company's strong growth trajectory and solid earnings position it well in the competitive drug manufacturing industry.
Bottom Line
Investors should keep an eye on Eli Lilly's upcoming earnings report on October 29, 2026, for further insights into its performance. Additionally, the continued activity from institutional investors like Anderson Hoagland may signal confidence in the company's future prospects.
Related Filing Alerts
Source: Anderson Hoagland's 13F filing on $LLY (Oct 23, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts